These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29272749)

  • 21. Correctors modify the bicarbonate permeability of F508del-CFTR.
    Fiore M; Picco C; Moran O
    Sci Rep; 2020 May; 10(1):8440. PubMed ID: 32439937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An overview on chemical structures as ΔF508-CFTR correctors.
    Spanò V; Montalbano A; Carbone A; Scudieri P; Galietta LJV; Barraja P
    Eur J Med Chem; 2019 Oct; 180():430-448. PubMed ID: 31326599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis.
    Awatade NT; Uliyakina I; Farinha CM; Clarke LA; Mendes K; Solé A; Pastor J; Ramos MM; Amaral MD
    EBioMedicine; 2015; 2(2):147-53. PubMed ID: 26137539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel tricyclic pyrrolo-quinolines as pharmacological correctors of the mutant CFTR chloride channel.
    Renda M; Barreca M; Borrelli A; Spanò V; Montalbano A; Raimondi MV; Bivacqua R; Musante I; Scudieri P; Guidone D; Buccirossi M; Genovese M; Venturini A; Bandiera T; Barraja P; Galietta LJV
    Sci Rep; 2023 May; 13(1):7604. PubMed ID: 37165082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of 6,9-dihydro-5H-pyrrolo[3,2-h]quinazolines as a new class of F508del-CFTR correctors for the treatment of cystic fibrosis.
    Barreca M; Renda M; Spanò V; Montalbano A; Raimondi MV; Giuffrida S; Bivacqua R; Bandiera T; Galietta LJV; Barraja P
    Eur J Med Chem; 2024 Oct; 276():116691. PubMed ID: 39089001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. VX-809 and related corrector compounds exhibit secondary activity stabilizing active F508del-CFTR after its partial rescue to the cell surface.
    Eckford PD; Ramjeesingh M; Molinski S; Pasyk S; Dekkers JF; Li C; Ahmadi S; Ip W; Chung TE; Du K; Yeger H; Beekman J; Gonska T; Bear CE
    Chem Biol; 2014 May; 21(5):666-78. PubMed ID: 24726831
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Journey on VX-809-Based Hybrid Derivatives towards Drug-like F508del-CFTR Correctors: From Molecular Modeling to Chemical Synthesis and Biological Assays.
    Parodi A; Righetti G; Pesce E; Salis A; Tomati V; Pastorino C; Tasso B; Benvenuti M; Damonte G; Pedemonte N; Cichero E; Millo E
    Pharmaceuticals (Basel); 2022 Feb; 15(3):. PubMed ID: 35337072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and biological evaluation of thiazole derivatives on basic defects underlying cystic fibrosis.
    Pesce E; Pedemonte N; Leoni A; Locatelli A; Morigi R
    Bioorg Med Chem Lett; 2020 Nov; 30(21):127473. PubMed ID: 32784089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lumacaftor-rescued F508del-CFTR has a modified bicarbonate permeability.
    Ferrera L; Baroni D; Moran O
    J Cyst Fibros; 2019 Sep; 18(5):602-605. PubMed ID: 30738802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Revertants, low temperature, and correctors reveal the mechanism of F508del-CFTR rescue by VX-809 and suggest multiple agents for full correction.
    Farinha CM; King-Underwood J; Sousa M; Correia AR; Henriques BJ; Roxo-Rosa M; Da Paula AC; Williams J; Hirst S; Gomes CM; Amaral MD
    Chem Biol; 2013 Jul; 20(7):943-55. PubMed ID: 23890012
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanistic Approaches to Improve Correction of the Most Common Disease-Causing Mutation in Cystic Fibrosis.
    Bali V; Lazrak A; Guroji P; Matalon S; Bebok Z
    PLoS One; 2016; 11(5):e0155882. PubMed ID: 27214033
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Computational Exploration of Potential CFTR Binding Sites for Type I Corrector Drugs.
    Lester A; Sandman M; Herring C; Girard C; Dixon B; Ramsdell H; Reber C; Poulos J; Mitchell A; Spinney A; Henager ME; Evans CN; Turlington M; Johnson QR
    Biochemistry; 2023 Aug; 62(16):2503-2515. PubMed ID: 37437308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The investigational Cystic Fibrosis drug Trimethylangelicin directly modulates CFTR by stabilizing the first membrane-spanning domain.
    Laselva O; Molinski S; Casavola V; Bear CE
    Biochem Pharmacol; 2016 Nov; 119():85-92. PubMed ID: 27614011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potentiation of BKCa channels by cystic fibrosis transmembrane conductance regulator correctors VX-445 and VX-121.
    Kolski-Andreaco A; Taiclet S; Myerburg MM; Sembrat J; Bridges RJ; Straub AC; Wills ZP; Butterworth MB; Devor DC
    J Clin Invest; 2024 Jul; 134(16):. PubMed ID: 38954478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-Content Surface and Total Expression siRNA Kinase Library Screen with VX-809 Treatment Reveals Kinase Targets that Enhance F508del-CFTR Rescue.
    Perkins LA; Fisher GW; Naganbabu M; Schmidt BF; Mun F; Bruchez MP
    Mol Pharm; 2018 Mar; 15(3):759-767. PubMed ID: 29384380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rescue of CFTR NBD2 mutants N1303K and S1235R is influenced by the functioning of the autophagosome.
    Liu Q; Sabirzhanova I; Yanda MK; Bergbower EAS; Boinot C; Guggino WB; Cebotaru L
    J Cyst Fibros; 2018 Sep; 17(5):582-594. PubMed ID: 29936070
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological chaperones improve intra-domain stability and inter-domain assembly via distinct binding sites to rescue misfolded CFTR.
    Baatallah N; Elbahnsi A; Mornon JP; Chevalier B; Pranke I; Servel N; Zelli R; Décout JL; Edelman A; Sermet-Gaudelus I; Callebaut I; Hinzpeter A
    Cell Mol Life Sci; 2021 Dec; 78(23):7813-7829. PubMed ID: 34714360
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined effects of VX-770 and VX-809 on several functional abnormalities of F508del-CFTR channels.
    Kopeikin Z; Yuksek Z; Yang HY; Bompadre SG
    J Cyst Fibros; 2014 Sep; 13(5):508-14. PubMed ID: 24796242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction.
    Brewington JJ; McPhail GL; Clancy JP
    Expert Rev Respir Med; 2016; 10(1):5-17. PubMed ID: 26581802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In Silico and In Vitro Evaluation of the Mechanism of Action of Three VX809-Based Hybrid Derivatives as Correctors of the F508del CFTR Protein.
    Baroni D; Scarano N; Ludovico A; Brandas C; Parodi A; Lunaccio D; Fossa P; Moran O; Cichero E; Millo E
    Pharmaceuticals (Basel); 2023 Dec; 16(12):. PubMed ID: 38139828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.